Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy
- PMID: 19229108
- PMCID: PMC2648692
- DOI: 10.1172/JCI36612
Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy
Abstract
Sarcolemma-associated neuronal NOS (nNOS) plays a critical role in normal muscle physiology. In Duchenne muscular dystrophy (DMD), the loss of sarcolemmal nNOS leads to functional ischemia and muscle damage; however, the mechanism of nNOS subcellular localization remains incompletely understood. According to the prevailing model, nNOS is recruited to the sarcolemma by syntrophin, and in DMD this localization is altered. Intriguingly, the presence of syntrophin on the membrane does not always restore sarcolemmal nNOS. Thus, we wished to determine whether dystrophin functions in subcellular localization of nNOS and which regions may be necessary. Using in vivo transfection of dystrophin deletion constructs, we show that sarcolemmal targeting of nNOS was dependent on the spectrin-like repeats 16 and 17 (R16/17) within the rod domain. Treatment of mdx mice (a DMD model) with R16/17-containing synthetic dystrophin genes effectively ameliorated histological muscle pathology and improved muscle strength as well as exercise performance. Furthermore, sarcolemma-targeted nNOS attenuated alpha-adrenergic vasoconstriction in contracting muscle and improved muscle perfusion during exercise as measured by Doppler and microsphere circulation. In summary, we have identified the dystrophin spectrin-like repeats 16 and 17 as a novel scaffold for nNOS sarcolemmal targeting. These data suggest that muscular dystrophy gene therapies based on R16/17-containing dystrophins may yield better clinical outcomes than the current therapies.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2648692/bin/JCI0936612.f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2648692/bin/JCI0936612.f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2648692/bin/JCI0936612.f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2648692/bin/JCI0936612.f4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2648692/bin/JCI0936612.f5.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2648692/bin/JCI0936612.f6.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2648692/bin/JCI0936612.f7.gif)
![Figure 8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2648692/bin/JCI0936612.f8.gif)
Comment in
-
NO more muscle fatigue.J Clin Invest. 2009 Mar;119(3):448-50. doi: 10.1172/jci38618. J Clin Invest. 2009. PMID: 19306501 Free PMC article.
Similar articles
-
Dystrophin R16/17 protein therapy restores sarcolemmal nNOS in trans and improves muscle perfusion and function.Mol Med. 2019 Jul 2;25(1):31. doi: 10.1186/s10020-019-0101-6. Mol Med. 2019. PMID: 31266455 Free PMC article.
-
Dystrophin R16/17-syntrophin PDZ fusion protein restores sarcolemmal nNOSμ.Skelet Muscle. 2018 Nov 22;8(1):36. doi: 10.1186/s13395-018-0182-x. Skelet Muscle. 2018. PMID: 30466494 Free PMC article.
-
α2 and α3 helices of dystrophin R16 and R17 frame a microdomain in the α1 helix of dystrophin R17 for neuronal NOS binding.Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):525-30. doi: 10.1073/pnas.1211431109. Epub 2012 Nov 26. Proc Natl Acad Sci U S A. 2013. PMID: 23185009 Free PMC article.
-
Nitric oxide synthase deficiency and the pathophysiology of muscular dystrophy.J Physiol. 2014 Nov 1;592(21):4627-38. doi: 10.1113/jphysiol.2014.274878. Epub 2014 Sep 5. J Physiol. 2014. PMID: 25194047 Free PMC article. Review.
-
Role of neuronal nitric oxide synthase (nNOS) in Duchenne and Becker muscular dystrophies - Still a possible treatment modality?Neuromuscul Disord. 2018 Nov;28(11):914-926. doi: 10.1016/j.nmd.2018.09.001. Epub 2018 Sep 11. Neuromuscul Disord. 2018. PMID: 30352768 Review.
Cited by
-
DMD deletions underlining mild dystrophinopathies: literature review highlights phenotype-related mutation clusters and provides insights about genetic mechanisms and prognosis.Front Neurol. 2024 Jan 15;14:1288721. doi: 10.3389/fneur.2023.1288721. eCollection 2023. Front Neurol. 2024. PMID: 38288333 Free PMC article. Review.
-
N-terminal titin fragment: a non-invasive, pharmacodynamic biomarker for microdystrophin efficacy.Skelet Muscle. 2024 Jan 16;14(1):2. doi: 10.1186/s13395-023-00334-y. Skelet Muscle. 2024. PMID: 38229112 Free PMC article.
-
When Size Really Matters: The Eccentricities of Dystrophin Transcription and the Hazards of Quantifying mRNA from Very Long Genes.Biomedicines. 2023 Jul 24;11(7):2082. doi: 10.3390/biomedicines11072082. Biomedicines. 2023. PMID: 37509720 Free PMC article.
-
Prolonged voluntary wheel running reveals unique adaptations in mdx mice treated with microdystrophin constructs ± the nNOS-binding site.Front Physiol. 2023 Jun 26;14:1166206. doi: 10.3389/fphys.2023.1166206. eCollection 2023. Front Physiol. 2023. PMID: 37435312 Free PMC article.
-
Duchenne muscular dystrophy: disease mechanism and therapeutic strategies.Front Physiol. 2023 Jun 26;14:1183101. doi: 10.3389/fphys.2023.1183101. eCollection 2023. Front Physiol. 2023. PMID: 37435300 Free PMC article. Review.
References
-
- Stamler J.S., Meissner G. Physiology of nitric oxide in skeletal muscle. Physiol. Rev. 2001;81:209–237. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases